Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Cell viability of JFCR-028-3 parental and lorlatinib intermediate resistant cells treated with the indicated concentration of LY2090314 for 72 h (n = 3). Each point represents the mean ± SD of three replicates. Cell viability of b JFCR-028-3 parental and c–e lorlatinib intermediate resistant cells treated with the indicated concentration of lorlatinib in the presence or absence of a fixed concentration of LY2090314 for 72 h (n = 3). Each point represents the mean ± SD of three replicates. f Immunoblot analysis of indicated proteins after treatment of JFCR-028-3 parental and JFCR-028-3-LR1000#1 cells with indicated concentrations of lorlatinib in the absence or presence of LY2090314 for 0, 3, and 24 h. GAPDH was used as a loading control. g Apoptosis assay of JFCR-028-3-LR1000#1 cells treated with the 30 nM lorlatinib and 100 nM LY2090314. Apoptosis was evaluated using Annexin-V and PI staining after 72 h of the indicated drug treatment. The apoptotic cells were shown in red square and the percentage of apoptotic cells is shown in red value.